June, 2017

FUNDING OPPORTUNITIES:

Featured Funding Opportunities

- **Find NIH Grants:**

- **Weekly Grant ListServ:**

- **Find Other Federal Funding:**
  - National Science Foundation: http://www.nsf.gov/funding/
  - Congressionally Directed Medical Research Program: http://cdmrp.army.mil/
  - Centers for Disease Control, See: http://www.grants.gov/

- **Find Funding with COS/Pivot:**
  - Pivot: http://pivot.cos.com/
  - You can search for funding with Pivot Funding Opportunities, identify experts and collaborators with Pivot Profiles, and promote your research with a Pivot Profile.

- **Find Restricted Awards:** –Limited subs-must be USF DSR pre-reviewed

- **Find USF Sources List: Medicine:**
  - http://health.usf.edu/nocms/medicine/research/CurrentFundingOpps.pdf

- **Find funding by category:**

Selected NIH Funding Opportunities –June, 2017

**Aging:**
**Novel Cell Non-autonomous Mechanisms of Aging (R01)(RFA-AG-18-009)**
Application Due Date: **October 3, 2017**, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date.

**Potential Effects of Metformin on Aging and Age-Related Conditions: Small-Scale Clinical Studies and Secondary Analysis of Controlled Clinical Studies (R01) (PA-17-073)**
Application Due Date: **Standard dates apply**, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

**Comparative Biology of Neurodegeneration (R21)(PAR-17-039)**
Application Due Date: **Standard dates apply**, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
Aging Research Dissertation Awards to Increase Diversity (R36)(PAR-17-025)
Application Due Date: **Standard dates apply**, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

**Anergy, Immunology and Infectious Diseases:**
Innovation for HIV Vaccine Discovery (R01)(PAR-17-263)
Application Due Date: **August 1, 2017**, by 5:00 PM local time of applicant organization. All types of applications allowed for this funding opportunity announcement are due on these dates.

**Dysregulation of Immune Cell Regulatory Pathways by Mtb in the Context of HIV Infection**
(R61/R33)(RFA-AI-17-010)
Application Due Date: **August 1, 2017**, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date.

**HIV/AIDS and the Tumor Niche** (R01)(RFA-CA-17-030)
Application Due Date: **August 7, 2017**, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

**Sleep Health and Circadian Biology in HIV-Related Comorbidities** (R01)(RFA-HL-18-005)
Application Due Date: **August 9, 2017**, by 5:00 PM local time of applicant organization. All types of applications allowed for this funding opportunity announcement are due on this date.

**Exploring Novel RNA Modifications in HIV/AIDS and Substance Use Disorders** (R01)(RFA-DA-18-008)
Application Due Date: **August 17, 2017**, by 5:00 PM local time of applicant organization. All types of applications allowed for this funding opportunity announcement are due on this date.

**Exploring Novel RNA Modifications in HIV/AIDS and Substance Use Disorders** (R21)
Application Due Date: **August 17, 2017**, by 5:00 PM local time of applicant organization. All types of applications allowed for this funding opportunity announcement are due on this date.

**Role of Myeloid Cells in Persistence and Eradication of HIV-1 Reservoirs from the Brain** (R01)
Application Due Date: **September 6, 2017**, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

**Role of Myeloid Cells in Persistence and Eradication of HIV-1 Reservoirs from the Brain** (R21)
Application Due Date: **September 6, 2017**, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date.

**Avenir Award Program for Research on Substance Abuse and HIV/AIDS** (DP2)(RFA-DA-18-004)
Application Receipt Date: **Nov 13, 2017** by 5:00 PM local time of applicant organization. All types of applications allowed for this funding opportunity announcement are due on this date.

**Silencing of HIV-1 Proviruses** (R61/R33)(RFA-AI-17-013)
Application Due Date: **December 6, 2017**, by 5:00 PM local time of applicant organization. All types of applications allowed for this funding opportunity announcement are due on this date.

**In Vitro and Animal Model Studies on HBV/HIV Co-Infection** (R01)(PA-17-280)
Application Due Date: **Standard AIDS dates apply**, by 5:00 PM local time of applicant organization. All types of applications allowed for this funding opportunity announcement are due on these dates.

**In Vitro and Animal Model Studies on HBV/HIV Co-Infection (R21)(PA-17-281)**
Application Due Date: **Standard AIDS dates apply**, by 5:00 PM local time of applicant organization. All types of applications allowed for this funding opportunity announcement are due on these dates.

**Modeling of Infectious Disease Agent Study Research Projects (R01)(PAR-17-267)**
Application Due Date: **Standard AIDS dates apply**, by 5:00 PM local time of applicant organization. All types of AIDS and AIDS-related applications allowed for this funding opportunity announcement are due on these dates.

**Innovations in HIV Testing, Adherence, and Retention to Optimize HIV Care Continuum Outcomes (R21)(PA-17-181)**
Application Due Date: **Standard AIDS dates apply**, by 5:00 PM local time of applicant organization.

**Innovations in HIV Testing, Adherence, and Retention to Optimize HIV Care Continuum Outcomes (R01)(PA-17-182)**
Application Due Date: **Standard AIDS dates apply**, by 5:00 PM local time of applicant organization.

**Targeted Implementation Science to Achieve 90/90/90 Goals for HIV/AIDS Prevention and Treatment (R01) (PA-17-194)**
Application Due Date: **Standard dates apply**, by 5:00 PM local time of applicant organization.

**Targeted Implementation Science to Achieve 90/90/90 Goals for HIV/AIDS Prevention and Treatment (R21) (PA-17-195)**
Application Due Date: **Standard dates apply**, by 5:00 PM local time of applicant organization.

**Cancer:**

**Inter-organelle Communication in Cancer (R01)(PAR-17-203)**
Application Due Date: **August 16, 2017**, by 5:00 PM local time of applicant organization.

**Inter-organelle Communication in Cancer (R21)(PAR-17-204)**
Application Due Date: **August 16, 2017**, by 5:00 PM local time of applicant organization.

**Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes (R01) (PA-17-239)**
Application Due Date: **Standard dates apply**, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

**Mechanisms of Alcohol-associated Cancers (R21)(PA-17-219)**
Application Due Date: **Standard dates apply**, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

**Mechanisms of Alcohol-associated Cancers (R01)(PA-17-220)**
Application Due Date: **Standard dates apply**, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
Cardiovascular related:
Developing Biomarkers for Trastuzumab-induced Cardiotoxicity (R30)(RFA-FD-17-006)
Application Due Date: July 10, 2017, by 11:59 PM Eastern Time. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Basic Research in Calcific Aortic Valve Disease (R01)(RFA-HL-18-010)
Application Due Date: October 18, 2017, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date.

Integrated Approaches to HIV-Related Heart, Lung, Blood, and Sleep (HLBS) Comorbidities (R01)(RFA-HL-18-004)
Application Due Date(s): December 15, 2017, by 5:00 PM local time of applicant organization.

Diabetes related:
Identification of Mechanisms Mediating the Effects of Sleep on Diabetes-Related Metabolism in Humans (R01)(RFA-DK-16-005)
Application Due Date(s): October 11, 2017, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

Biomarkers for Diabetes, Digestive, Kidney and Urologic Diseases Using Biosamples from the NIDDK Repository (R01)(PAR-17-123)
Application Due Date: Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

Addressing Health Disparities in NIDDK Diseases (R01)(PA-17-021)
Application Due Date: Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

Assay Development and Screening to Discover Therapeutic or Imaging Agents for Diseases of Interest to the NIDDK (R01)(PA-16-374)
Application Due Date: Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

Genomics:
HIV Drug Resistance: Genotype-Phenotype-Outcome Correlations (R01)(PA-17-291)
Application Due Date: Standard AIDS dates apply, by 5:00 PM local time of applicant organization. All types of applications allowed for this funding opportunity announcement are due on these dates.

HIV Drug Resistance: Genotype-Phenotype-Outcome Correlations (R21)(PA-17-292)
Application Due Date: Standard AIDS dates apply, by 5:00 PM local time of applicant organization. All types of applications allowed for this funding opportunity announcement are due on these dates.

Center for Inherited Disease Research (CIDR) High Throughput Sequencing and Genotyping Resource Access (X01)(PAR-17-269)
Application Due Date: **Applications are accepted by continuous receipt** by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date.

**NIDDK Central Repositories Non-renewable Sample Access (X01)(PAR-17-270)**
Application Due Date: **October 31, 2017**, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

**From Genomic Association to Causation: A Convergent Neuroscience Approach for Integrating Levels of Analysis to Delineate Brain Function in Neuropsychiatry (Collaborative R01)(PAR-17-252)**
Application Due Date: **Standard dates apply**, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

**From Genomic Association to Causation: A Convergent Neuroscience Approach for Integrating Levels of Analysis to Delineate Brain Function in Neuropsychiatry (R01)(PAR-17-253)**
Application Due Date: **Standard dates apply**, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

**Genomics of HIV/AIDS Drug Response and Co-Morbidities (R01)(PA-16-435)**
Application Due Date(s): **Standard AIDS dates**, by 5:00 PM local time of applicant organization. All types of AIDS and AIDS-related applications allowed for this funding opportunity announcement are due on these dates. **The first AIDS application due date** for this FOA is May 7, 2017.

**K Awards:**
**NCI Transition Career Development Award to Promote Diversity (K22)(PAR-17-069)**
Application Due Date: **Standard dates apply**, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

**NIMH Career Transition Award for Tenure-Track and Tenured Intramural Investigators (K22)(PAR-16-389)**
Application Due Date: Applications are **due on the 9th of each month**, by 5:00 PM local time of applicant organization.

**Prenatal, Neonatal, Perinatal and Pediatric:**
**NICHD Exploratory/Developmental Research Grant (R21)(PA-17-259)**
Application Due Date: **Standard dates apply**, by 5:00 PM local time of applicant organization.

**Development of Appropriate Pediatric Formulations and Pediatric Drug Delivery Systems (R01)(PAR-17-193)**
Application Due Date: **Standard dates apply**, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

**Fertility Status as a Marker for Overall Health (R01)(PA-17-091)**
Application Due Date: **Standard dates apply**, by 5:00 PM local time of applicant organization. The **first standard application due date** for this FOA is **June 5, 2017**.

**Fertility Status as a Marker for Overall Health (R21)(PA-17-092)**
Application Due Date: **Standard dates apply**, by 5:00 PM local time of applicant organization. The first standard application due date for this FOA is **June 16, 2017**.

**Neurological:**

**Advancing Our Understanding of the Brain Epitranscriptome (R21)(PAR-17-152)**
Application Due Date: **Standard dates apply**, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

**Advancing our Understanding of the Brain Epitranscriptomics (R01)(PAR-17-153)**
Application Due Date: **Standard dates apply**, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

**Translational Research:**

**Translational Research in Pediatric and Obstetric Pharmacology and Therapeutics (R21)(PAR-17-187)**
Application Due Date: **August 7, 2017**, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

**Translational Research in Pediatric and Obstetric Pharmacology and Therapeutics (R03)(PAR-17-188)**
Application Due Date: **August 7, 2017**, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

**Translational Research in Pediatric and Obstetric Pharmacology and Therapeutics (R01)(PAR-17-189)**
Application Due Date: **August 7, 2017**, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

**Collaborative Research Projects to Enhance Applicability of Mammalian Models for Translational Research (Collaborative R01)(PAR-17-244)**
Application Due Date: **Standard dates apply**, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

**Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01)(PAR-17-245)**
Application Due Date: **Standard dates apply**, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

- **Find Help with Grants:**
  - Grant Writing tips: [http://www.usf.edu/research-innovation/train/documents/grantwriting-tips.pdf](http://www.usf.edu/research-innovation/train/documents/grantwriting-tips.pdf)